Physician profile
James Eric Rose
NPI 1740299957
$3,993.43
in general payments reported to CMS, 2019-2025
27 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2021: $140 · 2022: $267 · 2023: $622 · 2024: $1,259 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,296 · Education: $40.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,295.89 |
| Education | $40.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.23 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $717.86 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $378.46 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.67 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $215.18 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $200.22 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $187.18 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $180.13 | 2024-2025 | Resmetirom, Rezdiffra |
| Gilead Sciences, INC. | $141.62 | 2022-2025 | |
| Celltrion USA INC. | $137.57 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $120.14 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $112.19 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $80.11 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $77.26 | 2019-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $63.48 | 2024-2025 | Iqirvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $49.90 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $36.66 | 2021-2023 | |
| Pfizer INC. | $32.89 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.91 | 2021-2024 | |
| Novo Nordisk INC | $31.57 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $22.47 | 2024 | Zeposia |
| Amgen INC. | $18.85 | 2025 | Uplizna |
| Nestle Healthcare Nutrition INC. | $14.38 | 2023 | |
| Braintree Laboratories, INC. | $14.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.65 | 2025 | Voquezna |
| Medtronic, INC. | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.